A61K 40/31
Chimeric antigen receptors [car]
Official title: Chimeric antigen receptors [CAR]
A61K40/31 (Chimeric antigen receptors [car]) appears on 2,120 US grants and 6,191 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,120
- Published applications
- 6,191
- Assignees
- 1,475
- Inventors
- 8,733
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 3 |
| 2004 | 1 | 2 |
| 2005 | 0 | 1 |
| 2006 | 1 | 2 |
| 2007 | 0 | 1 |
| 2008 | 2 | 0 |
| 2009 | 0 | 4 |
| 2010 | 2 | 3 |
| 2011 | 1 | 6 |
| 2012 | 1 | 8 |
| 2013 | 4 | 18 |
| 2014 | 6 | 35 |
| 2015 | 11 | 41 |
| 2016 | 22 | 92 |
| 2017 | 34 | 152 |
| 2018 | 50 | 258 |
| 2019 | 94 | 378 |
| 2020 | 178 | 516 |
| 2021 | 190 | 682 |
| 2022 | 247 | 748 |
| 2023 | 245 | 736 |
| 2024 | 333 | 960 |
| 2025 | 389 | 847 |
| 2026 | 307 | 698 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Chimeric receptor genes and cells transformed therewith327US 7,741,465 B12010
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013